文献速递心脑血管急症

超薄支柱生物可降解聚合物西罗莫司洗脱支架与薄支柱耐久聚合物依维莫司洗脱支架在经皮冠状动脉血运重建中的比较:BIOSCIENCE随机试验5年结果

Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
PubMed 文献 · Lancet · 2018-08-28
一句话结论在全体接受经皮冠状动脉介入治疗的患者中,超薄支柱生物可降解聚合物西罗莫司洗脱支架与薄支柱耐久聚合物依维莫司洗脱支架的5年靶病变失败风险相似,但前者的全因死亡和非心血管死亡发生率较高,需在正在进行的临床试验中仔细观察。

BIOSCIENCE随机、单盲、多中心、非劣效性试验比较了生物可降解聚合物西罗莫司洗脱支架与耐久聚合物依维莫司洗脱支架在慢性稳定性冠心病或急性冠脉综合征患者中的效果。5年随访显示,靶病变失败(心源性死亡、靶血管心肌梗死和临床指示的靶病变血运重建的复合终点)在两组间无显著差异(20.2% vs 18.8%;RR 1.07,95%CI 0.88-1.31;p=0.487)。全因死亡在生物可降解聚合物西罗莫司洗脱支架组显著更高(14.1% vs 10.3%;RR 1.36,95%CI 1.06-1.75;p=0.017),主要由非心血管死亡差异驱动。两组5年明确支架血栓累积发生率无差异(均为1.6%;RR 1.02,95%CI 0.51-2.05;p=0.950)。

要点

  • 5年靶病变失败累积发生率:生物可降解聚合物西罗莫司洗脱支架组20.2% vs 耐久聚合物依维莫司洗脱支架组18.8%,RR 1.07(95%CI 0.88-1.31),p=0.487,无显著差异。
  • 5年全因死亡率:生物可降解聚合物西罗莫司洗脱支架组14.1% vs 耐久聚合物依维莫司洗脱支架组10.3%,RR 1.36(95%CI 1.06-1.75),p=0.017,生物可降解聚合物西罗莫司洗脱支架组更高。
  • 全因死亡差异由非心血管死亡驱动。
  • 5年明确支架血栓累积发生率两组均为1.6%,RR 1.02(95%CI 0.51-2.05),p=0.950,无差异。
  • 作者认为,生物可降解聚合物西罗莫司洗脱支架组较高的全因和非心血管死亡率需要在正在进行的临床试验中仔细观察。

适用人群与场景

  • 慢性稳定性冠心病或急性冠脉综合征患者,接受经皮冠状动脉介入治疗。

研究设计与关键结果

  • 随机、单盲、多中心、非劣效性BIOSCIENCE试验,纳入2119例患者,2012年3月1日至2013年5月31日招募,2008例(95%)完成5年随访。
  • 主要终点靶病变失败(心源性死亡、靶血管心肌梗死和临床指示的靶病变血运重建的复合终点)5年累积发生率:生物可降解聚合物西罗莫司洗脱支架组20.2% vs 耐久聚合物依维莫司洗脱支架组18.8%,RR 1.07(95%CI 0.88-1.31),p=0.487。
  • 全因死亡率:生物可降解聚合物西罗莫司洗脱支架组14.1% vs 耐久聚合物依维莫司洗脱支架组10.3%,RR 1.36(95%CI 1.06-1.75),p=0.017,差异由非心血管死亡驱动。
  • 5年明确支架血栓累积发生率:两组均为1.6%,RR 1.02(95%CI 0.51-2.05),p=0.950。

证据类型、等级与局限

  • 随机、单盲、多中心、非劣效性试验(BIOSCIENCE,NCT01443104)。
  • 作者指出,生物可降解聚合物西罗莫司洗脱支架组较高的全因和非心血管死亡率需要在正在进行的临床试验中仔细观察。

对床旁实践的改变

  • 在全体接受经皮冠状动脉介入治疗的患者中,选择超薄支柱生物可降解聚合物西罗莫司洗脱支架或薄支柱耐久聚合物依维莫司洗脱支架时,5年靶病变失败风险相似。
  • 作者认为,生物可降解聚合物西罗莫司洗脱支架组较高的全因和非心血管死亡率需要在正在进行的临床试验中仔细观察。

指南或共识出处

  • BIOSCIENCE随机试验5年结果,发表于Lancet。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Drug-eluting stents combining an ultrathin cobalt-chromium stent platform with a biodegradable polymer eluting sirolimus have been shown to be non-inferior or superior to thin-strut, durable-polymer, everolimus-eluting stents in terms of 1 year safety and efficacy outcomes.

METHODS: In the randomised, single-blind, multicentre, non-inferiority BIOSCIENCE trial, we compared biodegradable-polymer sirolimus-eluting stents with durable-polymer everolimus-eluting stents in patients with chronic stable coronary artery disease or acute coronary syndromes. Here, we assess the final 5-year clinical outcomes of BIOSCIENCE with regards to the primary clinical outcome of target lesion failure, which was a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation. The primary analysis was done by intention to treat. The BIOSCIENCE trial is registered with ClinicalTrials.gov, number NCT01443104.

FINDINGS: 2008 (95%) of 2119 patients recruited between March 1, 2012, and May 31, 2013, completed 5 years of follow-up. Target lesion failure occurred in 198 patients (cumulative incidence 20·2%) treated with biodegradable-polymer sirolimus-eluting stents and in 189 patients (18·8%) treated with durable-polymer everolimus-eluting stents (rate ratio [RR] 1·07, 95% CI 0·88-1·31; p=0·487). All-cause mortality was significantly higher in patients treated with biodegradable-polymer sirolimus-eluting stents than in those treated with durable-polymer everolimus-eluting stents (14·1% vs 10·3%; RR 1·36, 95% CI 1·06-1·75; p=0·017), driven by a difference in non-cardiovascular deaths. We observed no difference between groups in cumulative incidence of definite stent thrombosis at 5 years (1·6% in both groups; 1·02, 0·51-2·05; p=0·950).

INTERPRETATION: 5-year risk of target lesion failure among all-comer patients undergoing percutaneous coronary intervention is similar after implantation of ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents or thin-strut, durable-polymer, everolimus-eluting stents. Higher incidences of all-cause and non-cardiovascular mortality in patients treated with biodegradable-polymer stents eluting sirolimus than in those treated with durable-polymer stents eluting everolimus warrant careful observation in ongoing clinical trials.

FUNDING: Clinical Trials Unit of the University of Bern and Biotronik.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Pilgrim T, Piccolo R, Heg D, et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018. PMID: 30170848. doi:10.1016/S0140-6736(18)31715-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。